Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
From the pathological standpoint, NCWS patients only have a slight increase of intraepithelial lymphocytes, while antibodies to tissue transglutaminase (tTG) and villous atrophy, otherwise diagnostic features of celiac disease, are absent.
|
31834915 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The findings lend credence to a model of celiac disease where gluten-reactive T cells provide help to autoreactive TG2-specific B cells by involvement of gluten-TG2 complexes, and they outline a general mechanism of autoimmunity with autoantibodies being produced by ignorant B cells on provision of T cell help.
|
31727780 |
2020 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A Biocard celiac test that detects IgA antibodies to tissue transglutaminase in whole blood was used to screen for celiac disease in healthy first-grade children born in 2011 and 2012 who consumed gluten without restrictions.
|
31687014 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Considering antibody diagnostic performance based on AUC, enteric damage reflection and predictability at an early age, the anti-neo tTG check was the most effective diagnostic biomarker for pediatric CD.
|
31663117 |
2020 |
Celiac Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Medical records were reviewed for children with celiac disease confirmed by the presence of elevated tissue transglutaminase IgA levels and histologic changes consistent with the diagnosis of celiac disease on small bowel biopsy.
|
31552781 |
2020 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These new insights into the structure of TG2-gluten peptide complexes may help clarify the role of extracellular TG2 in CD autoimmunity and in other inflammatory diseases.
|
31547042 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Trials for tolerization in celiac disease aim for antigen specific tolerance to gluten, an environmental trigger, which may then halt the progression to autoimmunity targeting a self-antigen, tissue transglutaminase.
|
31476445 |
2019 |
Celiac Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The secondary outcome was celiac disease confirmed by intestinal biopsy or persistently high tissue transglutaminase autoantibody levels.
|
31408136 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although small intestinal biopsy remains the diagnostic 'gold standard', highly sensitive and specific serological tests, such as tissue transglutaminase, endomysial and deamidated gliadin peptide antibodies, have become gradually more important in the diagnostic work-up of celiac disease.
|
31331324 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Subsequently, the patient was found to have markedly elevated celiac disease antibodies (deamidated gliadin IgG and tissue transglutaminase IgA) and to be HLA DQ2 and DQ8 allele positive on genotyping for celiac disease.
|
31274556 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The pathogenesis of fibrillar-type DH may differ from that of granular-type DH, which is dependent on gluten and in which IgA antibodies to tissue transglutaminase (the main antigen in GSE) are detected.
|
31106757 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Erratum to "Association of Tissue Transglutaminase Antibody Titer with Duodenal Histological Changes in Children with Celiac Disease".
|
31097958 |
2019 |
Celiac Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DH and CD share a similar genetic background, small bowel mucosal alterations, and an autoimmune response against tissue transglutaminase in the serum and small bowel.
|
31093998 |
2019 |
Celiac Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
From 1993 through January 2017, 161 children, using repeated tissue transglutaminase (tTGA) screening, were identified with CD autoimmunity (CDA) and persistent tTGA positivity; of these children, 85 fulfilled CD criteria of biopsy-verified histopathology or persistently high tTGA levels.
|
31082869 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Celiac disease was diagnosed in four donors with positive tissue transglutaminase antibodies, establishing a prevalence of 1.68% (95% confidence interval 1.15-2.3) for celiac disease autoimmunity and 0.21% for celiac disease (95% confidence interval 0.07-0.5%).
|
31019710 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Frequencies of three serum markers of CD [tissue transglutaminase (TTG) IgA, endomysial (EMA) IgA, and deaminated gliadin peptide (DGP) IgA] were determined by enzyme-linked immunoassay (ELISA).
|
30977932 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We observed elevated titers of anti-IDs in asymptomatic patients with predisposition to CD and demonstrated that anti-ID depletion from the serum restores a detectable humoral response against TG2.
|
30635394 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Even lacking sequence identity, it imitates functionally the endogenous tissue transglutaminase, known to be the autoantigen of celiac disease and representing an undisputable key player in celiac disease initiation and progress.
|
30619787 |
2018 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serological and clinical data were collected, and "triple criteria" for coeliac disease comprised transglutaminase 2 antibodies >10× the upper limit of normal, positive endomysium antibodies, and appropriate genetics without requirement of symptoms.
|
30592070 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Despite low sequence identity, it imitates functionally its family member, the endogenous tissue transglutaminase, which is the autoantigen of celiac disease.
|
30543926 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The prevalence of CD in most parts of the world is estimated at 1:100-1:150 and its diagnosis is based on the presence of circulating autoantibodies (anti-TG2) and the histological detection of villous atrophy.
|
30528262 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aimed to define the frequency of small bowel mucosal TG2-specific plasma cells in coeliac disease patients with varying disease activity, and to investigate whether the frequency correlates with serum and small intestinal TG2-targeting antibodies as well as mucosal morphology and the number of intraepithelial lymphocytes.
|
30522434 |
2018 |
Celiac Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Celiac disease (CD) is an intestinal issue activated by the inappropriate immune reaction towards gluten protein of wheat, rye, barley, oats, and autoantigen, tissue transglutaminase.
|
30516838 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aimed to discover biomarkers of CeD derived from neoepitopes of deamidated gliadin peptides (DGP) and tTG fragments and to determine if immune reactivity against these epitopes can identify patients with CeD with mucosal healing.
|
30342033 |
2019 |
Celiac Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multi-functional transglutaminase 2 (TG2), which possesses protein cross-linking and GTP hydrolysis activities, is involved in various cellular processes, including apoptosis, angiogenesis, wound healing, and neuronal regeneration, and is associated with many human diseases, including inflammatory disease, celiac disease, neurodegenerative disease, diabetes, tissue fibrosis, and cancers.
|
30321187 |
2018 |